Micreos founder & CEO Mark Offerhaus | Image credit: Micreos
The Hague-based Micreos, a Dutch/Swiss biotech company, announced on Tuesday, October 25, that it has secured €25M in growth funding in a fresh round.
The company will use the funds to invest in its specialised skincare brand, Gladskin, for people suffering from inflammatory skin conditions such as acne, eczema, and rosacea. Micreos claims that it has helped thousands of people in Europe and the USA.
Gladskin is based in the Netherlands with offices in the USA, Germany, France, and the UK.
The company will deploy the funds toward its pharmaceutical programmes, including the clinical development of endolysins against staphylococci (including MRSA) for Bloodstream Infections, Atopic Dermatitis, Diabetic Foot Ulcers, and Cutaneous T-cell Lymphoma.
The announcement comes over an year after raising €32M in a fresh round of funding. A few days back the company announced the appointment of the company’s antimicrobial vector engineering team, Dr. Matthew Dunne, Dr. Samuel Kilcher, and Dr. Anja Keller, who joined them from the Swiss Federal Institute of Technology (ETH Zurich). 
The trio will be responsible for developing synthetic precision antimicrobials for medical indications across infectious and inflammatory diseases.
Led by CEO Mark Offerhaus, Micreos develops targeted antibacterial solutions based on endolysin- and phage technology as a sustainable alternative to antibiotics.
Endolysins are naturally occurring enzymes that can target only harmful bacteria while preserving the beneficial ones that form an important part of our natural defence, often referred to as our microbiome. Endolysins are safe and environmentally friendly, says the company.
The company claims to have pioneered the development of this technology and brought the world the first endolysin-based precision antibacterials.
Offerhaus says, “With this restructuring, we align business and market requirements, enabling each business to pursue its growth strategy. It is especially important for the pharmaceutical business, which is capital-intensive and extremely promising. As a result, direct investments in Micreos Pharma, headed by Matt Regan, will now be possible.”
Apart from the group headquarters in The Hague, Micreos Pharmaceuticals has headquarters in Zug, Switzerland, a Discovery and Technology Centre in Wädenswil, Switzerland, and a Development Team in Bilthoven, the Netherlands.
october
No Events
november
No Events
december
No Events
Want to know how HRs across Europe are rethinking retention and performance management post pandemic? Get this FREE whitepaper by PERSONIO now!
jobbio_sidebar.widget({
slug: ‘silicon-canal-jobs’,
container: ‘sidebar’,
location: ‘jobs’,
count: 2,
type: ‘multiple’,
content: ‘jobs’
});
Silicon Canals 2014-2022 | Website: Bright Idiots
Silicon Canals 2014-2022 | Website: Bright Idiots
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.